Introduction: Highly effective, combination therapy for chronic hepatitis C virus (HCV) infection is now available. Current cure rates are close to 100% and applicable to all patients irrespective of race, age, severity of liver disease or viral genotype. Remarkably for persistent infection, current treatment is recommended for as little as 12 weeks; recent studies suggest even shorter courses. In contrast to interferon-based therapy, present regimens have few side effects and serious adverse events are rare. The success and safety of these regimens has stimulated interest in the possible eventual elimination of HCV. Barriers to elimination include cost of drugs and finding patients in the community less likely to interact with medical services who are a potential reservoir of infection.
Introduction
World Health Organization (WHO) estimates that approximately 80 million people are infected with hepatitis C virus (HCV) worldwide and that 700,000 people die each year from complications arising from that infection. 1 The last 40 years have witnessed staggering progress in the recognition and treatment of HCV from the clinical syndrome of unexplained post-transfusion hepatitis that was soon shown to be distinct from both Hepatitis A and B, through the identification of the virus itself in 1989, 2,3 the widespread introduction of testing for HCV in the early 1990s, the introduction of often ineffective and unpleasant interferon (IFN)-based therapy, to an infection that can now be cured in most cases with a short course of well tolerated, highly effective oral, direct acting antiviral (DAA) therapy. Current evidence suggests that DAA therapy for patients with advanced liver disease awaiting liver transplantation will inhibit viral replication promptly and so may halt disease with a modest chance that liver transplantation can be avoided. 4 Most of those who clear HCV but still need a liver graft will be able to look forward to a posttransplant course free from HCV infection, in marked contrast to just 3 years ago, when HCV graft infection was inevitable with a high risk of graft injury. For those with significant liver fibrosis, there is strong presumptive evidence that DAA therapy will reduce both morbidity and mortality. The benefits of DAA therapy in patients with early stage liver fibrosis are less immediate, but there is good evidence that inhibiting HCV replication permanently will halt fibrosis progression, with substantial improvement in symptoms. Given the impressive efficacy of DAA therapy, with cure rates exceeding 95% in most scenarios, treatment now offers the potential for elimination of HCV. Elimination describes the reduction of the regional prevalence of an infectious disease to zero and global prevalence to a negligible amount, whereas eradication describes reducing global prevalence to zero. 5 Eradication of HCV is not a realistic goal currently. The WHO Global Health Sector Strategy on Viral Hepatitis was published recently 6 and emphasizes an international focus on elimination of HCV. Elimination of HCV in developing countries has very different challenges to those in the UK, which is the focus of this review. Is elimination of HCV in the UK an achievable goal? There are two main barriers. The first is the price of DAAs. The current cost of DAA therapy is such that offering treatment to all patients with mild disease, with no immediate threat to life, provokes significant 'funder anxiety' simply because of the large number of HCV-infected individuals. Short-term economic views that restrict access to DAAs need to be balanced against the long-term consequences and cost of HCV infection both with regard to the care of that individual awaiting treatment as well as to the community (by reducing the pool of HCV-infected persons). The second issue, if elimination is considered a realistic political as well as a clinical goal, is finding all those patients in the community who remain 'invisible' to the medical profession that are unaware of their infection or disinclined to engage with health services to undergo therapy. This review explores these issues.
Epidemiology and natural history of hepatitis C
The worldwide population prevalence of chronic hepatitis C is in the region of 1%. 1 This varies between countries and within regions, but prevalence reflects blood borne spread of the virus, most commonly through intravenous drug use, past use of infected blood products, contaminated surgical instruments, historical vaccination programmes and vertical transmission. The frequency of sexual transmission approaches 0%, but may be higher in those with HIV co-infection or men who have sex with men. 7 The majority of those exposed to HCV are unaware of infection at that time and become infected chronically, based on the small proportion with no history of illness found to be anti-HCV positive but HCV-RNA negative and who are presumed to have cleared the virus spontaneously. Chronic infection is more likely to occur with increasing age, male sex and particular HLA class II alleles and IFNL3 SNPs, while an acute presentation favours spontaneous elimination of HCV. 8, 9 There is marked heterogeneity in the clinical course in those with chronic infection. Retrospective studies quote a risk of progression from chronic infection to cirrhosis of 20% over 2-3 decades. 10 This estimate is likely to reflect referral bias, 11 and more recent prospective studies are consistent with that view, demonstrating a much lower chance of progression. The largest prospective study followed 568 patients over a 24-year period. 12 These patients were infected through transfusion and only 23 (4%) developed end stage liver disease. The risk factors for progressive liver injury and evolution to cirrhosis in those with chronic HCV infection are age (both age at exposure and current age, the latter reflecting duration in many cases where the time of infection cannot be determined), male sex, excessive alcohol consumption, obesity and co-infection with HIV. From the mid-1990s, treatment comprised IFN subcutaneously each day; pegylation then allowed treatment to be administered thrice weekly. Treatment was for 1 year with SVR rates in the region of 10-25% patients. 13 The response rate in those with genotype 1 was low and in those with significant liver fibrosis rarely exceeded 10%. The low response rate and the very high incidence of side effects coupled with the long duration of therapy required real dedication on the part of the patient. Efficacy increased to 40-50% when pegylated IFN was combined with ribavirin but at the expense of further toxicity, while those patients most in need of therapy had the lowest response rates. The first protease inhibitors entered mainstream practice in 2011 for patients with genotype 1 and were used in combination with pegylated IFN and ribavirin. These improved SVR to 75%, but with an appreciable increase in morbidity.
Evolution of treatments for hepatitis C
The addition of NS5A and NS5B inhibitors allowed IFN-free regimens to become available and is now the standard of care in all international guidelines. 14, 15 These regimens are highly effective, extremely well tolerated and prescribed over a very short period. Typically, a 12-week course of therapy generates SVR12 rates in the region of 95%. At the annual meeting of AASLD in November 2016, preliminary data were presented suggesting that with particular combinations SVR exceeding 98% can be achieved with just 8 weeks therapy. Table 1 summarizes the evolution of hepatitis C treatments. Table 2 gives the currently available DAA therapies.
Effect of treatment on natural history of hepatitis
For patients with advanced fibrosis, SVR is associated with reduced mortality. This has been best The DAA era is in its infancy, so fewer studies of the natural history after DAA-induced SVR have been published, and those that have are characterized by short follow-up. UK registry data, based only on patients with advanced disease treated with DAAs already show a reduction in decompensation events, but a similar probability of death and the risk of developing HCC. 4 The most likely explanation is that such patients already had HCC at the time of therapy, which continued to evolve after therapy was complete. While there is a concern that HCC may be more common after DAA therapy, 18, 19 it is generally anticipated that this finding represents the polarized population included in the registry and will not be reproduced when patients with less advanced liver disease are treated with DAAs. The overall expectation is that benefits of an SVR with DAAs will mirror those seen in the IFN era. For patients with early stage disease, the benefits of treatment are less well established. There is evidence of improvement in liver inflammatory grade and fibrosis stage. 20 Extrahepatic manifestations of HCV such as cryoglobulinaemic vasculitis and non-Hodgkin's lymphoma are improved by SVR. Physical, emotional and social health may also improve as a consequence of obtaining SVR. However, the majority of patients with HCV are not at significant risk of developing advanced liver disease or HCC. Whether such patients should be offered antiviral therapy is a contentious subject of discussion across the globe. The medical case for therapy is overwhelming, but the high cost of therapy is such that funding bodies have not responded with enthusiasm. An alternative approach to treating all comers is careful surveillance of those with mild disease, since those with progressive or significant fibrosis may be identified using non-invasive tests, including elastography, or one of a number of the blood tests in evolution for hepatic fibrosis and then introducing treatment before significant complications occur. 21, 22 This approach has not yet been costed with sufficient accuracy to justify comparison or adoption. While the cost of treating patients with advanced liver disease is readily balanced against immediate health costs, careful surveillance has also enormous long-term costs to Health Services in terms of clinics, investigations and communications. Further, it abandons many patients to poor physical and psychological health over extended periods and does not address the number of HCV-infected individuals in the community who might infect others. Elimination of hepatitis C Given the effectiveness and side effect profile of DAA therapy, the potential for population-based elimination of hepatitis C is compelling. UK modelling studies suggest that improving diagnosis and treatment rates would improve outcome. If diagnosis and treatment were increased in the UK to 140% and 115%, respectively, by 2018, it is predicted that by 2020 the total number of HCV cases would decrease by 27%, HCV-related cirrhosis by 62%, HCV-related decompensation by 65%, HCVrelated HCC by 52% and HCV-related deaths by 51%. 23 For populations with high rates of infection, such as persons who inject drugs (PWIDs), the impact of more focused diagnostic and treatment strategies could be even more marked. 24 A model of DAA treatment 'scale up' demonstrates a likely reduction in the prevalence of HCV among PWIDs from 35% to 10% if patients with all fibrosis stages are treated. 25 While there is a great enthusiasm for populationbased screening and elimination strategies amongst the HCV community, some leading authors are concerned that there is not enough evidence to support population-based screening or elimination strategies. 26 
Treatment failure with DAAs
Although response rates are very high, a small number of patients do not attain SVR with DAAs in current use, which in some may be related to a DAA resistance. In addition, re-infection has been reported. However, evolving resistance to DAAs would be a significant barrier to the elimination of HCV. The main targets for DAAs are the NS3/4A protease, the NS5B polymerase and the NS5A replication complex. The error-prone HCV polymerase, combined with rapid viral replication introduces marked viral diversity, enabling the virus to side-step host immunity; however, with evolving mutations in the DAA, target proteins comes the potential to develop resistance. Cross-resistance to compounds in the same inhibitor class, especially for the NS3 protease and NS5A inhibitors, remains a concern.
These mutations are found in low frequency, but may be selected by therapy with DAAs. HCV variants resistant to a DAA targeting one particular viral protein will remain susceptible to another DAA targeting another viral protein, but combination therapy may fail occasionally with selection of a therapy driven variant with substitutions in multiple targets. In practice, the frequency of DAA resistant variants is low, but this remains a key area for continued surveillance. 27 
An approach to elimination in the UK
With an assumption that elimination of HCV is both possible and desirable, the following areas of development are required.
Epidemiology
Robust epidemiological data are required to focus elimination strategies effectively. Accurate prevalence, incidence and transmission risk data allow targeted prevention and screening and provision of effective care networks. In the UK, an annual report is published by Public Health England. 28 This includes data from national mortality statistics, PWID services, Hospital Episode Statistics and NHS data sources. Important findings include:
• An estimated 50% PWID report adequate needle exchange provision.
• An estimated 50% PWID test positive for HCV antibody.
• There were around 9000 treatment initiations in 2015 from 6000 in 2014.
• 400 deaths in 2015 were from end stage liver disease or HCC in association with HCV as ascertained from death certificate entries.
While these data are important, a fully resourced national surveillance system would generate more robust data to allow effective identification of population 'hotspots' and new epidemics, where treatment and preventative strategies could be focussed. A similar international focus on HCV epidemiology is also important. 29 
Prevention
In the UK, the most common mode of transmission of HCV is through intravenous drug use. 30 The following strategies have been shown to reduce the spread of blood borne viruses in this group. 8 • Community based education and counselling.
• Access to sterile needles and drug paraphernalia through community-based needle exchange programmes.
• Effective substance misuse programmes.
• Education for people who use non-injectable illicit drugs to prevent them becoming PWIDs.
• Targeted prevention for epidemics.
Internationally, prevention of iatrogenic blood borne virus transmission with blood product screening, the use of sterile needles and surgical equipment, and avoidance/safe practice with multi-dose medication vials is also important. An effective vaccine is not a real prospect a present but would revolutionize prevention.
Screening
HCV testing of high prevalence populations will identify cases effectively. 8 In the UK, such populations, whenever screened, are found to have HCV in large numbers including homeless services, drug and alcohol centres, high prevalence general practices and criminal justice settings. Screening of recipients of blood transfusions before 1992 (although most of those likely to have been infected in this manner in the UK have been traced), patients on haemodialysis (screened routinely in the UK) or those in specific demographic groups (such as those born between 1945 and 1965 in the USA 31 ) are additional strategies. Population-based screening may be effective, but would be contentious.
Care networks that provide universal access to treatment
Community programmes that offer IFN-based therapy are effective. 32 DAA therapy is more effective than IFN-based therapy and easier to administer with fewer side effects. Early data support its effectiveness in the community setting for patients in opiate substitution programmes. 33 Models of care with automatic reminders for testing of patients in primary care, which include nurse-led education programmes and provide co-ordination with mental health and substance misuse services have been shown to increase testing, treatment and cure. 34 Ultimately a system should develop in which patients with uncomplicated HCV are tested and treated in primary care and community settings without the need to attend hospital. To obtain this goal, education of primary care providers is required initially through collaboration between primary and secondary care. The current 'hub and spoke' model of care in the UK must be used to facilitate rather than hinder this development. A 'Commissioning for Quality and Innovation' (CQUIN) scheme has been implemented by NHS England, which aims to encourage engagement with non-specialist services and provides a financial incentive to do so. 35 It remains to be seen whether central hub incentives improve community-based care across spoke as well as hub providers and thereby entire networks.
Value for money of DAA therapy DAA therapy is highly effective and has been found to provide value for money by bodies including the National Institute of Health and Care Excellence. 36 However, a major barrier to population-based elimination remains the significant cost of DAA therapy, which is illustrated in Figure 1 , where the wide international variation in the cost of ledipasvir and Sofosbuvir is given. The two main pharmaceutical industries in the field at present, Gilead and Abbvie, reported net incomes of $3497 and $1610 M, respectively, in the quarter ending 30 June 2016. 38 To eradicate HCV infection effectively and efficiently, drug costs must be reduced significantly and there is clearly scope for this. While it is the responsibility of the pharmaceutical industry to cut costs, healthcare providers must create a competitive environment that catalyses the process. Indeed, NHS England has already negotiated substantial DAA price reductions.
Funding models for DAA therapy
Three main approaches to funding DAA therapy have been employed for budgetary rationing in high income countries. Firstly, a price capped approach whereby a budget is allocated by healthcare commissioners for HCV treatment and once that is exceeded treatment is stopped. Secondly, a numbers capped approach whereby a certain number of treatments are allocated per year, which is the approach taken in the UK. Thirdly, a volume capped approach whereby a price is negotiated between commissioners and the pharmaceutical industry for a certain volume of treatments. The latter approach has been employed in Australia and led to the same number of treatments by Australian General Practitioners over a 2-week period in March 2016 as that of the whole of England in an overlapping 3-month period. 39 
Strategy
The WHO recently published the Global Health Sector Strategy on Viral Hepatitis. 6 This document emphasizes a need for national strategies for hepatitis C elimination. In our view, the UK national strategy should have the following two phases. $0.00 P o la n d U n it e d S t a t e s P o r t u g a l S lo v e n ia S p a in G e r m a n y I t la y J a p a n N e t h e r la in tandem with phase 1 and encompass the following aspects:
(1) Identification and focus on areas of high incidence, prevalence and unmet need; (2) Promoting collaboration between secondary care and healthcare providers in areas of high HCV prevalence such as general practice serving the homeless or areas with high levels of social deprivation, prisons, drug and alcohol services. The opportunity to treat such patients immediately is especially important for patients who are more often 'invisible' to care services and whose lifestyles may favour propagation of HCV; (3) Empowering primary care providers to treat patients with HCV; (4) Funding research that identifies the most efficacious models of care; (5) Effectively monitoring treatment rates so that high value treatment can be negotiated and appropriately budgeted for.
Collaboration between the HCV community, commissioners and patient groups should facilitate this strategy, which we believe would be acceptable to all parties.
Conclusion
DAA therapy marks an exciting era in HCV treatment that could lead to elimination of the virus. Collaboration and drug price reductions are the key to obtaining this goal.
